

1 **Personalized Computational Heart Models with T1-Mapped Fibrotic Remodeling Predict**  
2 **Risk of Sudden Death Risk in Patients with Hypertrophic Cardiomyopathy**

3

4 Ryan P. O'Hara<sup>1</sup>, Edem Binka<sup>2</sup>, Adityo Prakosa<sup>1</sup>, Stefan L. Zimmerman<sup>3</sup>, Mark J. Cartoski<sup>4</sup>, M.  
5 Roselle Abraham<sup>5</sup>, Dai-Yin Lu<sup>5</sup>, Patrick M. Boyle<sup>6</sup>, Natalia A. Trayanova<sup>1\*</sup>

6

7 <sup>1</sup>Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, US. <sup>2</sup>Divi-  
8 sion of Pediatric Cardiology, Johns Hopkins School of Medicine, Baltimore, MD, US. <sup>3</sup>Depart-  
9 ment of Radiology, Johns Hopkins School of Medicine, Baltimore, MD, US. <sup>4</sup>Division of Pediat-  
10 ric Cardiology, Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE, US. <sup>5</sup>Division  
11 of Cardiology, University of California San Francisco, San Francisco, CA, US. <sup>6</sup>Department of  
12 Bioengineering, University of Washington, Seattle, WA, US.

13

14 **\*Correspondence:** Natalia A. Trayanova, 3400 N Charles Street, 216 Hackerman Hall, Balti-  
15 more, MD 21218, USA. Tel: +14105164375 | E-mail: [ntrayanova@jhu.edu](mailto:ntrayanova@jhu.edu)

16

17 **Competing Interests:** The authors declare that no competing interests exist.

18

19 **Word count excluding Materials and Methods, References, and Figure Legends: 3971**

20 **Abstract:**

21 Hypertrophic cardiomyopathy (HCM) causes sudden cardiac death (SCD) due to ventricular  
22 arrhythmias (VA) manifesting from myocardial fibrosis proliferation. Current clinical risk  
23 stratification criteria inadequately identify at-risk patients in need of primary prevention of VA.  
24 Here, we use mechanistic computational modeling of the heart to analyze how HCM-specific  
25 remodeling of the heart promotes arrhythmogenesis and to develop a personalized strategy to  
26 forecast risk of VAs in these patients. We combine contrast-enhanced cardiac magnetic-  
27 resonance (CMR) imaging and T1 mapping data to construct digital replicas of HCM patient  
28 hearts that represent the patient-specific distribution of focal and diffuse fibrosis and evaluate the  
29 substrate propensity to VA. Our analysis indicates that the presence of diffuse fibrosis, which is  
30 rarely assessed in these patients, increases arrhythmogenic propensity. In forecasting future VA  
31 events in HCM patients, the imaging-based computational heart approach achieved 84.6%,  
32 76.9%, and 80.1% sensitivity, specificity, and accuracy, respectively, and significantly  
33 outperformed current clinical risk predictors. This novel VA risk assessment may have the  
34 potential to prevent SCD and help deploy primary prevention appropriately in HCM patients.

35

36 **Introduction:**

37 Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death  
38 (SCD) in the young and is a significant cause of sudden death in adults.(Maron, 2004) The  
39 disease, with an incidence of 1 in 500, presents with progressive myocardial fibrosis which can  
40 create substrates for ventricular arrhythmias (VA) leading to SCD in patients who are typically  
41 asymptomatic.(Galati *et al.*, 2016; Olivotto *et al.*, 2012) Implantable cardioverter defibrillator  
42 (ICD) deployment, a procedure that carries risk of potential complications and morbidity, is used  
43 as primary prevention of SCD due to VA in patients with HCM.(Lambiase *et al.*, 2016;  
44 Jayatilleke *et al.*, 2004) However, current risk stratification criteria outlined by the American  
45 College of Cardiology Foundation/American Heart Association (ACCF/AHA) and European  
46 Society of Cardiology (ESC) fail to accurately identify all patients at risk for SCD, leading to  
47 suboptimal rates of appropriate ICD implantation.(Gersh *et al.*, 2011; O'Mahony *et al.*, 2014;  
48 Schinkel *et al.*, 2012) Thus, many HCM patients receive ICDs without deriving any health  
49 benefits, while others are not adequately protected. Development of accurate means to stratify  
50 SCD risk due to VA in HCM patients for guidance of ICD deployment is an important unmet  
51 clinical need.

52 Cardiac magnetic resonance (CMR) imaging with late gadolinium enhancement (LGE)  
53 has unparalleled capability in the detection and quantification of scar and dense fibrosis(Prakosa  
54 *et al.*, 2014). In HCM, myocardial fibrosis takes the form of both dense (focal) and diffuse  
55 fibrosis, with histopathological evidence showing diffuse fibrosis as the hallmark feature of the  
56 disease.(Galati *et al.*, 2016) Diffuse fibrosis, however, is not well captured by standard LGE-  
57 CMR. Instead, post-contrast T1 mapping, a parametric imaging modality, has been used to  
58 visualize diffuse fibrosis in patients with HCM.(Chu *et al.*, 2017; Ellims *et al.*, 2012) We have


59 previously developed a computational modeling approach (virtual heart) to predict SCD risk due  
60 to VA in post-infarction patients,(Arevalo *et al.*, 2016) We hypothesized that a new personalized  
61 virtual-heart technology, one that entails constructing fusion electrophysiological models based  
62 on the distribution of both dense and diffuse fibrosis, as acquired by the two different CMR  
63 modalities, would be predictive of the propensity of the HCM-remodeled substrate to VAs and  
64 could thus be used to assess SCD risk due to VA in this patient population.

65 The goal of this study is to create a personalized virtual-heart approach based on the  
66 combination of post-contrast T1 mapping and LGE-CMR and to employ it 1) to analyze how  
67 HCM-specific remodeling promotes arrhythmogenesis and 2) in a targeted strategy to forecast  
68 risk of VA in HCM patients. In a proof-of-concept patient cohort, we assess the predictive  
69 capability of the approach as compared to that of other clinical metrics for VA risk prediction in  
70 HCM.

71

## 72 **Results:**

73 The new approach to analyzing arrhythmogenic propensity in HCM patients developed  
74 here involved creating three-dimensional (3D) patient-specific electrophysiological ventricular  
75 models based on fusing data from LGE-CMR and post-contrast T1 mapping. Each model thus  
76 represented the personalized distribution of focal fibrosis (scar) and diffuse fibrosis. VA  
77 inducibility in each HCM patient's substrate was probed to determine VA risk for the patient and  
78 to understand the mechanisms of arrhythmogenesis, and specifically, the contribution of the  
79 individualized diffuse fibrosis distribution, which is rarely assessed in these patients. Conceptual  
80 overview of our approach to analyzing the arrhythmogenic propensity of HCM patient hearts is  
81 presented in Figure 1A.



82

83 **Figure 1. A.** Flowchart summarizing the virtual-heart VA risk stratification approach for HCM

84 patients. A combination of LGE-CMR and post-contrast T1 mapping is used to construct

85 personalized LV geometrical models with fibrotic remodeling. Incorporating HCM-specific

86 electrophysiological properties (action potential kinetics, conduction velocity) completes the

87 generation of each personalized LGE-T1 virtual heart, which is then used to assess VA

88 propensity in the substrate via rapid pacing. RV is shown in transparent gray. Dense fibrosis

89 (scar) is considered non-conductive. **B.** Fusing LGE-CMR and post-contrast T1 map information  
90 to generate the personalized, geometrical virtual-heart model. Top left: LV segmentation with in-  
91 termediate and high signal intensity thresholds of 3 (yellow) and 5 SD (purple), respectively, on  
92 short-axis LGE-CMR. Bottom left: Mid-ventricular post-contrast T1 map segmentation with re-  
93 laxation time thresholds of <350 (blue) and 350-450 ms (gray). Right: The thresholds of the  
94 LGE-CMR signal intensity were adjusted to new, personalized thresholds,  $T_{\text{Diffuse}}$  and  $T_{\text{Dense}}$ ,  
95 based on the T1 map (see text for detail). D: The new personalized signal intensity thresholds in  
96 the matching LGE-CMR slice were then applied to all LGE-CMR short-axis slices.

97

98

#### 99 **Patient characteristics:**

100 Twenty-six patients with HCM were included in this study. Demographic information for  
101 the cohort is provided in Table 1. All patients were adults (median age 53 years) and our cohort  
102 was 19% female. Thirteen of the 26 HCM patients experienced clinical VAs. Of the clinical pa-  
103 rameters that associate with SCD in HCM (FHSCD, unexplained syncope, MWT, Max LVOTG,  
104 Age, LA diameter; see Table 1 for abbreviations), there were no statistically significant differ-  
105 ences ( $P = 0.34, -, 0.65, 0.72, 0.98, 0.26$ ) between patients with and without clinical VA. There  
106 was no statistically significant difference in any of the other common clinical characteristics be-  
107 tween the two groups. Clinical data alone was not sufficient to accurately determine VA risk in  
108 this population.

109

110 **Table 1. Patient Characteristics (N=26)**

Clinical Characteristic	Patients without VA, n=13	Patients with VA, n=13	P value
Male	12 (92)	9 (69)	0.08
Age at CMR, years	49.7 [19-76]	49.8 [22-78]	0.98
NYHA III/IV	4 (31)	4 (31)	-
Myectomy	1 (8)	1 (8)	-
ASA	1 (8)	2 (15)	0.34
Amiodarone	0 (0)	1 (8)	0.34
Persistent AF	3 (23)	4 (31)	0.34
LA Diameter, mm	43.8 ± 6.3	38.3 ± 12.7	0.26
Max LVOTG, mmHg	57.8 [4-154]	50.8 [8-160]	0.72
MWT, mm	20.5 ± 5.0	19.6 ± 5.6	0.65
FS, %	38.0 ± 10.2	40.3 ± 10.8	0.40
FHSCD	3 (23)	4 (31)	0.34
Unexplained Syncope	3 (23)	3 (23)	-

111 Values are given as n (%), mean [range], or mean ± SD. P values were calculated using Student *t*  
 112 test ( $P \leq .05$  considered statistically significant). VA=ventricular arrhythmia; CMR=cardiac  
 113 magnetic resonance; ASA=alcohol septal ablation; AF=atrial fibrillation; LA=left atrium;  
 114 LVOTG=left ventricular outflow tract gradient; MWT=maximum wall thickness; FS=fractional  
 115 shortening; FHSCD=family history of sudden cardiac death.

116

117 **Assessment of HCM Structural Remodeling Using LGE-T1 Geometrical Models:**

118 To reconstruct the geometrical model of each patient’s heart, LGE-CMR and post-  
 119 contrast T1 mapping images were combined, creating a personalized LGE-T1 fusion model of  
 120 HCM ventricular geometry and structural remodeling. Figure 1B presents the “fusing” process,  
 121 in which an initial reconstruction of ventricular geometry and scar/fibrosis was performed from

122 the LGE-CMR images using standard “one-size-fits-all” thresholds, and then the relaxation times  
123 from the short-axis T1 map were used to define *personalized* signal intensity thresholds to  
124 delineate areas of diffuse fibrosis and scar (see Methods for detailed description). The  
125 personalized thresholds were unique to each patient. The additional personalization of the  
126 geometrical model furnished by the usage of the T1 mapping data ensured a comprehensive  
127 representation of the individualized structural remodeling in each patient heart.

128         Once the geometrical models were reconstructed, they were analyzed to determine  
129 whether the level (amount) and/or distribution of structural remodeling discriminate between pa-  
130 tients with and without clinical VA. The level of regional hypertrophy was first assessed, as  
131 measured by the wall thickness of the heart models. No statistically significant difference in re-  
132 gional hypertrophy was found at the septum ( $P=0.61$ ), anterior wall ( $P=0.84$ ), posterior wall  
133 ( $P=0.94$ ), and apex ( $P=0.73$ ) between heart models of patients with and without clinical VA, as  
134 shown in Table 2. These results indicated that the level of hypertrophy does not discriminate be-  
135 tween arrhythmogenic and non-arrhythmogenic substrates in HCM patients.

136

137 **Table 2. LV wall thickness in HCM patients with and without clinical VA**

	Patients without VA, n=13	Patients with VA, n=13	<i>P</i> value
<b>Wall Thickness (mean ± SD)</b>			
Septum, mm	11.3 ± 8.4	13.1 ± 9.2	0.61
Anterior, mm	11.3 ± 7.4	10.7 ± 7.3	0.84
Posterior, mm	11.1 ± 7.2	11.3 ± 7.3	0.94
Apex, mm	7.9 ± 5.3	7.2 ± 4.8	0.73

138 P values were calculated using Student *t* test ( $P \leq 0.05$  considered statistically significant).




139 Figure 2A and B presents a comparison between geometrical heart models of 2 patients  
140 (one with clinical VA and another without) reconstructed by combining LGE-CMR with T1 map-  
141 ping, and by using LGE-CMR only. In the latter models, the accepted “one-size-fits-all” thresh-  
142 olds of 3 and 5 times the standard deviation (SD) of the low-intensity mean were used to recon-  
143 struct dense fibrosis (scar) and diffuse fibrosis distributions (see Methods). In the former models,  
144 patient-specific thresholds from the T1 mapping were used to delineate dense and diffuse fibro-  
145 sis. As evident from the figure, using patient-specific signal intensity thresholding from the T1  
146 map resulted in a significantly higher amount of diffuse fibrosis in these two models ( $42.9 \pm$   
147  $3.4\%$  vs  $9.8 \pm 0.1\%$ ).

148 For all HCM LGE-T1 fusion models, the average threshold for diffuse fibrosis,  $T_{\text{Diffuse}}$ ,  
149 was  $1.1 \pm 0.7$ , significantly different from the corresponding LGE “one-size-fits-all value”, 3 SD.  
150 The average threshold for dense fibrosis,  $T_{\text{Dense}}$ , was  $5.1 \pm 0.5$ , not a significant change from the  
151 original 5 SD. The personalized threshold adjustment did not therefore result in a significant  
152 change in the amount of dense fibrosis for LGE-T1 models compared to LGE-only models (aver-  
153 ages of  $3.8 \pm 2.3$  vs  $3.2 \pm 1.3$ ,  $P=0.30$ ). However, it resulted in a significant change in diffuse  
154 fibrosis across all models, as illustrated in Fig. 2C ( $40.5 \pm 9.4\%$  for LGE-T1 vs  $8.9 \pm 1.7\%$  for  
155 LGE only,  $P<0.0001$ ).

156 No statistical differences were found in the amounts of diffuse fibrosis between LGE-T1  
157 models with and without clinical VA ( $P=0.53$ , confidence interval; CI: [36.8 44]) and between  
158 LGE-only models with and without clinical VA ( $P=0.94$ , CI: [8.25 9.53]; Fig.1B); also, no statis-  
159 tical difference was found in the amount of scar ( $3.7 \pm 2.2\%$  vs  $3.8 \pm 2.5$ ,  $P=0.91$  for LGE-T1  
160 and  $3.4 \pm 1.2\%$  vs  $3.0 \pm 1.5\%$ ,  $P=0.53$  for LGE only models). These results indicate that the im-  
161 aging characteristics of HCM structural remodeling, as visualized by the combination of LGE-

162 CMR and T1 mapping, cannot be used to discriminate between patients who will and will not de-  
163 velop clinical VA.

164



166 **Figure 2. A and B.** Examples of HCM personalized LV geometrical models with fibrotic remodeling (RV shown in transparent gray) reconstructed using LGE-CMR images with personalized  
167 eling (RV shown in transparent gray) reconstructed using LGE-CMR images with personalized  
168 T1-informed fibrosis segmentation thresholds (left) and using LGE-CMR images with one-size-  
169 fits-all fibrosis segmentation thresholds of 3 and 5 SD (right). There is significantly more diffuse  
170 fibrosis in the T1-adjusted models. **A:** Heart model from an HCM patient without clinical VA. **B:**  
171 Heart model from an HCM patient with clinical VA. **C.** Boxplot of the amount of diffuse fibrosis  
172 in LGE-T1 and LGE-only HCM geometrical models without clinical VA (LGE-T1: N=13,  
173 IQR=12.54; LGE Only: N=13, IQR=2.41; \*P<0.0001) and with clinical VA ((LGE-T1: N=13,  
174 IQR=14.44; LGE Only: N=13, IQR=2.46; \*\*P<0.0001).

175 **Figure 2 – source data 1; Spreadsheet including source data underlying Figure 2.**


176 For each geometrical model used in this study, the amount of diffuse fibrosis in each LGE-T1  
177 and LGE only model. Figure2\_SourceData.xlsx

178

### 179 **Assessment of Propensity to VA in HCM LGE-T1 Virtual Heart Models**

180       Once the geometrical models of all HCM patients were reconstructed, electrophysiologi-  
181 cal models were generated and used to assess the individualized propensity to VA by pacing from  
182 distributed ventricular sites, representing potential ectopy. Full detail is in Methods. A total of  
183 182 simulations ([26 patient heart] x [7 pacing locations]) were performed to probe propensity to  
184 VA induction in this cohort. To be able to better understand the role of T1-based diffuse fibrosis  
185 in arrhythmogenesis, we also repeated the simulations with LGE-only models.

186       Figure 3 presents reentrant arrhythmias induced (from sites marked with stars) in 3 LGE-  
187 T1 virtual hearts from patients with known clinical VAs. In all three cases, a single VA morphol-  
188 ogy was induced. In Figure 3, left, the VA localized in a region of interdigitated diffuse and dense  
189 fibrosis. In Figure 3 middle, there was a figure-of-eight reentry in a transmural region of diffuse  
190 fibrosis. In Figure 3 right, the VA shown was induced from two different pacing sites, one in the  
191 basal lateral and another in the inferoseptal wall and persisted also in a region of interdigitated  
192 diffuse and dense fibrosis.




193

194 **Figure 3.** VAs induced in 3 LGE-T1 virtual hearts from patients with known clinical VAs. **A.**

195 Reconstructed patient-specific geometrical models. **B.** Activation patterns of the reentry induced

196 from the pacing site(s) marked with star. Black regions did not activate during the timeframe

197 shown.



198

199 **Figure 4.** Relationship between T1-based diffuse fibrosis and VA inducibility in LGE-T1 and

200 LGE-only personalized virtual heart models of HCM patients. **A.** Comparison of the number of

201 unique VA morphologies between inducible LGE-T1 and LGE-only models for all VA-inducing

202 pacing sites. (LGE-T1: N=14, IQR=1; LGE Only: N=12, IQR=0.75; P=0.0538, CI [1.25, 1.75])

203 **B.** Correlation between amount of T1-based diffuse fibrosis and the number of unique VA mor-

204 phologies induced in LGE-T1 models (R=-0.3048, P=0.289). **C.** Distribution of the pacing sites

205 that induced VAs in LGE-T1 and LGE-only models.

206 **Figure 4 – source data 1; Spreadsheet including source data underlying Figure 4.**

207 For each geometrical model that reentry was induced, the number of unique VA morphologies

208 and amount of diffuse fibrosis in each LGE-T1 and LGE only model. Figure4\_SourceData.xlsx

209

210           Of the 26 LGE-T1 models, 14 were found inducible for VA in simulations. In contrast,  
211 only 12 LGE-only models were found inducible, indicating that the presence of diffuse fibrosis  
212 leads to increased VA inducibility. Figures 4 and 5 explore the mechanistic contributions to in-  
213 creased VA vulnerability in models with T1-based diffuse fibrosis.

214           Fig. 4A presents the number of unique VA morphologies induced by the pacing protocol.  
215 LGE-T1 models had a total of 24 unique VAs induced in them (out of total 32 VA episodes in-  
216 duced in the LGE-T1 models); in each model, there were between 1 and 3 different VA morphol-  
217 ogies. LGE-only models had a total of 15 unique VAs (with a total of 17 VA episodes induced in  
218 these models), with only 1 or 2 distinct VA morphologies induced per model. These results indi-  
219 cate that the presence of diffuse fibrosis as reconstructed from T1 mapping increases the number  
220 of unique VAs in each substrate. Fig.4B correlates the amount of diffuse fibrosis and the number  
221 of unique VAs ( $R=-0.3048$ ,  $P=0.289$ ) in LGE-T1 inducible models. The moderate negative corre-  
222 lation indicates that the distribution of diffuse fibrosis is more important than its amount as the  
223 mechanism of VA inducibility in the HCM-remodeled substrate. Figure 4C presents two bullseye  
224 plots with the 7 AHA regions in which pacing sites were located; shown are the number of pac-  
225 ing sites in each segment that elicited VAs in LGE-T1 and LGE-only inducible models. In the  
226 LGE-T1 models, out of the 98 pacing sites (7 pacing sites per each of the 14 inducible models),  
227 32 (33%) resulted in VA induction. In contrast, out of 84 pacing sites in the 12 LGE-only induci-  
228 ble models, 17 (20%) resulted in VA induction. Thus, the presence of T1-based diffuse fibrosis  
229 renders the substrate inducible from a larger number of ectopic locations, contributing to the  
230 overall increased vulnerability to VA. Interestingly, the sector with the pacing sites that induced  
231 most VAs (mid anteroseptal) and that with least (basal inferolateral) were the same in LGE-T1

232 and LGE-only models, indicating that the additional T1-based diffuse fibrosis localizes to the  
233 sectors with arrhythmogenic substrate in the LGE-only models. Overall, the distribution of pac-  
234 ing sites is the same (with small exception in the basal regions), but the number of sites per sec-  
235 tor increased with the presence of diffuse fibrosis.

236 Figure 5 explores the contribution of T1-based diffuse fibrosis to VA inducibility by com-  
237 paring arrhythmogenesis in individual models. Panel A shows, for the 13 patients with clinical  
238 VAs, the number of distinct VAs per patient model. First, LGE-T1 modeling documented cor-  
239 rectly VA occurrence in the digital substrates of 11 of the 13 patients with clinical VAs (com-  
240 pared to 9 LGE-only correct VA predictions); thus, the representation of T1-based diffuse fibro-  
241 ses increased the fidelity of the HCM virtual heart approach. Second, while the number of unique  
242 VA morphologies per inducible virtual heart increased in LGE-T1 models as compared to LGE-  
243 only (consistent with data in Fig. 4A), with LGE-T1 models having maximum 3 unique VAs (vs.  
244 2 in LGE-only) in the cohort, this plot points to interesting VA dynamics in individual substrates.  
245 Patients 5, 6, and 9 had the same level of arrhythmogenicity of the substrate (1 VA induced) re-  
246 gardless of the presence of T1-based diffuse fibrosis. An example of VA dynamics in these mod-  
247 els is shown in Fig.5B (patient 6). The additional diffuse fibrosis did not alter the location or di-  
248 rection of VA reentry; the reentry occurred in a region of dense scar in both types of models. Alt-  
249 hough the T1-based diffuse fibrosis (36.2%) in this patient augments the existing diffuse fibrosis  
250 of the LGE-only model (9.6%), there are no additional VA morphologies. However, the activa-  
251 tion dynamics were altered, with propagation being less organized.

252 In the reminder of the clinical-VA patients in Fig. 5A, the presence of T1-based diffuse  
253 fibrosis resulted in the occurrence of additional VA(s), on top of that (those) also present in the  
254 LGE-only model. Furthermore, there was not a strict correspondence between the VAs in the


255 LGE-only models and the equivalent ones in the LGE-T1 virtual heart in terms of VA locations  
256 and dynamics. This indicates that the arrhythmogenic substrate changes in a global fashion when  
257 T1-based diffuse fibrosis is considered. An example is presented in Fig. 5C (patient 9).

258 As VAs in HCM patients can occur under different circumstances and be documented by  
259 different means, there is no invasive clinical mapping data for these patients regarding the loca-  
260 tion and morphologies of the clinical VAs. However, two patients in this cohort underwent clini-  
261 cal electrophysiology studies that identified episodes of VA. The simulated VAs in the LGE-T1  
262 models matched the locations of the clinical VAs as documented by the chart review.

263 It remains unclear why patients 1 and 2 had non-inducible LGE-T1 substrates despite  
264 having clinical VAs. The amount of diffuse fibrosis in these 2 substrates ( $42.4 \pm 12.2\%$ ) was sim-  
265 ilar to that in the 11 inducible substrates ( $41.2 \pm 10.9\%$ ); similar was the finding regarding dense  
266 scar. Additionally, the maximum wall thickness and the thickness distribution fall into the same  
267 ranges as the averages of the cohort. It is possible that there have been other factors, including  
268 electrophysiological remodeling that the fusion substrate-based modeling approach presented  
269 here cannot capture. Despite incorrect prediction in 2 out of 26 patients in the HCM cohort, the  
270 VA risk prediction capabilities of the LGE-T1 virtual-heart approach significantly surpassed  
271 those of any current clinical risk assessment approaches, as detailed in the next section.



272



273  
 274 **Figure 5.** Comparison of arrhythmogenesis in HCM models of patients with clinical VAs. **A:**  
 275 Plot of the number of unique VA morphologies for patients with clinical VA using LGE-T1 LGE-  
 276 only models. **B and C:** Comparison of VAs in corresponding LGE-T1 and LGE-only models.  
 277 Pacing site(s) are marked with stars. Bullseye plots show the pacing site location (star) and the  
 278 location of the reentrant pathway in LGE-T1 (blue) and LGE-only (purple) models.  
 279 **Figure 5 – source data 1; Spreadsheet including source data underlying Figure 5.**

280 For each geometrical model with clinical VA, the number of unique VA morphologies in each  
281 LGE-T1 and LGE only model. Figure5\_SourceData.xlsx

282

### 283 **Assessment of the Capability of the HCM Virtual Heart VA Risk Prediction:**

284 After examining the mechanistic underpinning of arrhythmogenesis and the role of T1-  
285 based diffuse fibrosis in the HCM substrate, we conducted a comparison of our VA risk predictor  
286 capability with the clinical risk assessment guidelines of the American College of Cardiology  
287 Foundation (ACCF)/American Heart Association (AHA) and European Society of Cardiology  
288 (ESC). Results are presented in Table 3, illustrating that both existing clinical approaches were  
289 significantly inferior in predicting VA risk in this cohort. Of the 13 HCM patients with clinical  
290 VAs, the ACCF/AHA model predicted correctly 6 of the patients, while the ESC model predicted  
291 correctly 7 patients; the LGE-T1 virtual heart approach predicted correctly 11 patients. Overall,  
292 our LGE-T1 virtual heart technology exhibited higher accuracy and greater sensitivity and speci-  
293 ficity (80.1%, 84.6%, and 76.9%) as compared to the best performing corresponding metrics of  
294 the clinical risk assessment methodologies (46.2%, 53.9%, and 46.2% for accuracy, sensitivity,  
295 and specificity).

296 For completeness, data at the bottom of Table 3 quantifies the predictive capability of the  
297 substrate arrhythmogenesis approach when using LGE-only models (9 patients predicted cor-  
298 rectly out of 13). Interestingly, even without the additional T1 personalization (i.e. without ac-  
299 counting for T1-based diffuse fibrosis), the LGE-only virtual-heart technology outperformed the  
300 clinical risk stratifiers in this HCM cohort. This finding indicates that assessing the arrhythmo-  
301 genic propensity of the substrate is of paramount importance to HCM VA risk stratification, even  
302 when the distribution of diffuse fibrosis may not be accurately represented.

303

304 **Table 3. Predictive Capability of HCM Virtual-Heart Technology**

	Sensitivity	Specificity	PPV	NPV	Accuracy
ACCF/AHA Risk Model	46.2	46.2	46.2	46.2	46.2
ESC Risk Model	53.9	38.5	46.7	45.5	46.2
Virtual Heart Technology: LGE-T1	84.6	76.9	78.8	83.3	80.1
Virtual Heart Technology: LGE Only	69.2	76.9	75.0	71.4	73.1

305 ACCF=American College of Cardiology Foundation, AHA=American Heart Association,

306 ESC=European Society of Cardiology.

307

308 **Discussion:**

309 In this study, we presented a new personalized virtual heart approach for assessing  
310 arrhythmia risk in patients with HCM, which could be used in guiding clinical decisions for  
311 prophylactic ICD implantation. Our technology uses multiscale computational models of  
312 patients' hearts reconstructed on the basis of the fusion of imaging data from LGE-CMR and T1  
313 mapping. With the inclusion of information from post-contrast T1 mapping, a quantitative and  
314 parametric imaging modality, extensive diffuse fibrotic remodeling, which is a hallmark of  
315 HCM, is adequately represented. Here, this is done by adjusting the diffuse fibrosis intensity-  
316 based thresholds in model construction based on the T1 maps, while preserving the identification  
317 of dense scar from LGE-MRI. These are the first personalized heart models created with data  
318 from different types of CMR; previous personalized modeling approaches for VA assessment  
319 have utilized LGE-MRI scans in reconstructing model geometry/structure(Prakosa *et al.*, 2014;  
320 Cartoski *et al.*, 2019; Arevalo *et al.*, 2016). Once constructed, the mechanistic personalized  
321 electrophysiological models were used to analyze how HCM-induced remodeling, and

322 specifically the presence of diffuse fibrosis promotes arrhythmogenesis. Finally, the capability of  
323 our approach to forecast future VA events was assessed in the cohort of 26 HCM patients.

324 Presence of diffuse fibrosis has been suggested previously as a potential factor in  
325 increased risk of VA, in addition to focal scar. Previous studies have found associations between  
326 diffuse fibrosis and VA in non-ischemic dilated cardiomyopathies(Nakamori *et al.*, 2018) and  
327 mitral valve prolapse(Bui *et al.*, 2017). Additionally, diffuse ventricular fibrosis has been found  
328 to increase left atrial pressure, and may be a marker of atrial fibrillation recurrence post-  
329 ablation(Begg *et al.*, 2020). However, its contribution to arrhythmogenic propensity in HCM  
330 patients has never been assessed before. This study found that the presence of T1-based diffuse  
331 fibrosis resulted in the occurrence of new VAs, in addition to those arising from scar (as assessed  
332 by signal heterogeneities in LGE-MRI). Furthermore, T1-based diffuse fibrosis distribution  
333 rendered the substrate inducible from a larger number of ectopic locations, contributing to the  
334 overall increased vulnerability to VA.

335 In this retrospective proof-of-concept HCM study, the personalized LGE-T1 virtual heart  
336 technology demonstrated excellent performance in forecasting future VA events in HCM  
337 patients, achieving 84.6%, 76.9%, and 80.1% sensitivity, specificity, and accuracy, respectively.  
338 It outperformed both risk models used in current clinical practice, the ACCF/AHA and ESC  
339 models. Indeed, all 26 HCM patients in our study were deemed at high risk for SCD by the  
340 ACCF/AHA criteria and received ICDs for primary prevention, but only 13 patients, i.e. 50% of  
341 the cohort, actually experienced VA (appropriate ICD firing). Should our LGE-T1 virtual heart  
342 technology be proven to be a superior risk predictor in larger clinical studies, it would advance  
343 the management of patients with this complex disease, helping to ensure that those at high risk

344 for VA are adequately protected by ICDs and that unnecessary ICD implantations and the  
345 associated device complications are minimized.

346 The HCM virtual-heart technology's ability to comprehensively evaluate substrate  
347 arrhythmogenicity, as probed by rapid pacing delivered at a number of uniformly-distributed  
348 ventricular locations, is paramount to its superior performance. Even when using only LGE-  
349 CMR in model construction, which reliably detects focal scar (dense fibrosis) but underestimates  
350 the amount of non-ischemic fibrotic remodeling, our technology still offers VA risk assessment  
351 that is superior to the clinical risk models. However, the use of T1 maps in model construction  
352 confers a higher level of personalization in each patient heart model as compared to LGE only  
353 (i.e. personalized thresholds for segmentation), which ultimately translates into superior  
354 predictive capability.

355 HCM is a genetic disease that progresses throughout the life of the patient, and a cardiac  
356 event might be a phenotypic expression of the disease at any point of time. Therefore, we  
357 envision that in the clinical application of our technology, patients would be re-imaged at  
358 different time points and risk assessment repeated to account for changes in arrhythmia  
359 susceptibility over time as the diseased heart remodels.

360 The technology developed here charts a new direction in the use of biophysically-detailed  
361 heart modeling in the prognosis of rhythm disorders. A number of different imaging modalities  
362 used in patient assessment such as positron emission tomography (PET) or single-photon  
363 emission computerized tomography (SPECT) could also be integrated with LGE-CMR to  
364 construct hybrid heart computational models. Combining such computational approaches with  
365 machine learning techniques(Shade *et al.*, 2020a; Shade *et al.*, 2021) will enable the  
366 incorporation of additional patient clinical data, such as genetic information, phenotypic

367 characterization, as well as time series, such as electrocardiography (ECG), in the diagnosis and  
368 treatment of complex cardiac diseases.

369

### 370 **Study Limitations:**

371 Our study has a small sample size, limited by the fact that a number of LGE-CMR scans  
372 of HCM patients had imaging artifact, which prevented us from reconstructing a larger number  
373 of virtual hearts. Specifically, aliasing and motion artifacts were main causes for excluding  
374 patient data as well as incomplete scans (operator did not scan the entire LV). Further, in some  
375 patients there were discrepancies between the post-contrast T1 map and the matching LGE-CMR  
376 short axis scan as the in-plane resolution and slice thickness. However, these discrepancies were  
377 mitigated by binning the regions of fibrotic remodeling and electrophysiological changes instead of  
378 using a continuum.

379

### 380 **Methods:**

#### 381 **Study Overview:**

382 The methodology for assessing VA risk in HCM patients involves creating three-  
383 dimensional (3D) patient-specific electrophysiological ventricular models with data from LGE-  
384 CMR and post-contrast T1 mapping. Each model represents the personalized distribution of both  
385 focal fibrosis (scar) and diffuse fibrosis, both of which contribute to the formation of the  
386 arrhythmogenic substrate. VA inducibility in each HCM patient's substrate is probed to  
387 understand the mechanisms of arrhythmogenesis, and specifically the contributions to it of the  
388 focal and diffuse fibrosis distributions, and to determine VA risk for the patient. Conceptual  
389 overview is presented in Figure 1.

390 The predictive capabilities of the virtual-heart HCM VA risk stratifier were evaluated ret-  
391 rospectively in a proof-of-concept study using data from 26 HCM patients. We chose a cohort  
392 that was balanced between patients with VAs based on appropriate ICD firings (13 patients) and  
393 without arrhythmic events (the other 13 patients). All patients underwent implantation of clini-  
394 cally indicated ICDs. Virtual-heart predictions of VA risk, executed blindly, were compared to  
395 clinical outcomes.

396

### 397 **Study Population:**

398 The 26 patients were diagnosed with HCM based on the presence of left-ventricular (LV)  
399 wall thickness  $\geq 15$  mm on 2-dimensional echocardiography in the absence of other ventricular  
400 diseases, including hypertrophy of the right ventricle (RV), between 2011 and 2016 at Johns  
401 Hopkins Hospital.(Chu *et al.*, 2017) All patients were clinically referred for prophylactic ICD  
402 implantation, being deemed at high risk for VA based on clinician assessment. T1 maps and  
403 LGE-CMR were obtained pre-ICD implantation. Patients were followed for the primary end  
404 point of appropriate ICD firing due to VA. As stated above, of the 26 HCM patients, 13 (50%)  
405 had known VA episodes based on appropriate ICD firing. Patient clinical characteristics are  
406 shown in Table 1.

407

### 408 **Imaging Data:**

409 Patients whose imaging data was retrospectively used in this study had cardiac CMR  
410 examinations using a 1.5-T scanner (MAGNETOM Avanto; Siemens Healthcare, Erlangen,  
411 Germany) prior to ICD implantation. Short-axis LGE-CMR images were acquired as previously  
412 described.(Chu *et al.*, 2017) In addition, a single mid-ventricular short-axis post-contrast T1 map

413 was acquired 25 minutes after gadolinium injection using a MOLLI sequence.(Chu *et al.*, 2017)

414 All patient imaging data for model generation was obtained under IRB approval.

415

#### 416 **Geometrical Reconstruction of Patients' Hearts from T1 Maps and LGE-CMR Images:**

417 In generating HCM patients' virtual hearts, a geometrical model of each patient's heart  
418 was first reconstructed by combining the patient's LGE-CMR and post-contrast T1 mapping  
419 images. The LV myocardium was segmented from short-axis LGE-CMR as previously  
420 described.(Arevalo *et al.*, 2016) The RV was not reconstructed due to blood pool artifacts and the  
421 lack of hypertrophy and fibrotic substrate in HCM patients. The LGE-CMR was processed in the  
422 standard manner for reconstructing LV geometrical models of patients with ischemic(Arevalo *et*  
423 *al.*, 2016) or non-ischemic cardiomyopathy,(Shade *et al.*, 2020b; Cartoski *et al.*, 2019) which  
424 incorporate the distribution of scar and surrounding gray (border) zone. Specifically, as LGE-  
425 CMR is an image of relative intensity, the mean of the low signal intensity region in each image  
426 was determined, the latter representing myocardium without detectable fibrosis. The standard  
427 deviation (SD) of that mean value was used to threshold regions of intermediate ( $>3$  SD above  
428 the mean) and high ( $>5$  SD above the mean) signal intensity in the LV, representing fibrotic gray  
429 zone and focal scar. Figure 1B, top left, shows these thresholds applied to one LGE-CMR image.  
430 The same SD thresholds were used for all models.

431 Information from the patient's post-contrast T1 mapping was next incorporated in each  
432 geometrical heart model. As only a single short-axis mid-LV post-contrast T1 map (Fig.1B) was  
433 acquired for each patient, the matching slice (Fig.1B, top left) in the LGE-CMR stack was first  
434 found. The relaxation times from the short-axis T1 map were used to define new, *personalized*  
435 signal intensity thresholds (different from the "one-size-fits-all" thresholds of 3 and 5 SD of the



436 low-intensity mean) to delineate areas of intermediate and high signal intensities in the  
437 corresponding LGE slice. Specifically, regions in the LGE-CMR slice corresponding to short  
438 (<350ms) and intermediate (350-450ms) relaxation times in the T1 map were thresholded  
439 (Fig.1B). Based on evidence in histopathological studies(Ellims *et al.*, 2012; Iles *et al.*, 2008;  
440 Mewton *et al.*, 2011; Ellims *et al.*, 2014), these regions in the T1 map represent dense fibrosis  
441 (scar) and diffuse fibrosis.

442 The thresholds in the LGE-CMR slice, originally 3 and 5 SD of the mean signal intensity  
443 of the normal myocardium, were changed to new values ( $T_{\text{Diffuse}}$  and  $T_{\text{Dense}}$ , in units of SD,  
444 Fig.1B, bottom left) such that the amount and distribution of tissue of mid- and high signal  
445 intensity in the LGE-CMR slice matched those in the T1 map. The new personalized signal  
446 intensity thresholds in the matching LGE-CMR slice were then applied to all LGE-CMR short-  
447 axis slices (Fig.1B, right) for the given patient to complete the generation of the LGE-T1  
448 geometrical heart model (Fig.1A, middle); the personalized thresholds were unique to each  
449 patient. Using T1 mapping provided additional personalization of the model geometrical  
450 reconstruction and ensured a comprehensive representation of the individualized structural  
451 remodeling in each patient heart.

452 High resolution finite-element tetrahedral meshes, with an average resolution of  $355 \pm 69$   
453  $\mu\text{m}$ , were constructed directly from the ventricular segmentations using finite element analysis  
454 software (Mimics Innovation Suite; Materialise, Leuven, Belgium). Fiber orientations were  
455 applied to each mesh using a previously validated approach.(Bayer *et al.*, 2012; Prassl *et al.*,  
456 2009)

457

458 **Electrophysiological Properties in the HCM Virtual Hearts:**

459           The personalized 3D virtual hearts of HCM patients incorporated electrical functions  
460 from the cellular scale to the whole heart. Electrophysiological remodeling was incorporated in  
461 each virtual heart based on the reconstruction of heterogeneously distributed structural  
462 remodeling.

463           At the cellular level, in regions of non-fibrotic myocardium, the human ventricular  
464 myocyte model by ten Tusscher et al.(ten Tusscher and Panfilov, 2006) was used, with added  
465 representation of  $I_{NaL}$ (O’Hara *et al.*, 2011), as done in our previous studies.(Shade *et al.*, 2020b;  
466 Cartoski *et al.*, 2019; Arevalo *et al.*, 2016; Prakosa *et al.*, 2018) For regions of diffuse fibrosis,  
467 we modified the ionic conductances of the ten Tusscher model based on data reported by Coppini  
468 et al.(Coppini *et al.*, 2013) In the latter study, prolonged action potential duration and notch  
469 elevation following depolarization were observed in experimental recordings from myocytes in  
470 hypertrophied regions acquired via myectomy. As regions of hypertrophy in the HCM heart are  
471 also characterized with diffuse fibrotic remodeling, as per histopathological evidence,(Galati *et*  
472 *al.*, 2016) in the absence of experimental reports of specific ionic changes in regions of diffuse  
473 fibrosis, we used those reported by Coppini et al.(Coppini *et al.*, 2013) Figure 1A, middle, shows  
474 the action potentials implemented in regions of fibrotic and non-fibrotic myocardium.

475           At the tissue level, conductivity values along the longitudinal and transverse fiber  
476 directions in fibrotic and non-fibrotic myocardium were the same as previously implemented for  
477 non-ischemic patient heart models.(Shade *et al.*, 2020b) Dense fibrosis was considered  
478 electrically inexcitable. Once completed, the patient-specific HCM electrophysiological heart  
479 models were used to assess the patient’s risk of arrhythmia.

480

481   **Assessing VA Risk in the Personalized HCM Computational Models:**

482 Full details regarding the simulation of electrical activity in the virtual hearts can be  
483 found in previous publications.(Plank *et al.*, 2008; Prakosa *et al.*, 2018; Vigmond *et al.*, 2008)  
484 Briefly, these were finite element heart models, where simulation of electrical activity was  
485 performed in a monodomain representation of the myocardium using the software package  
486 CARP (<https://carp.medunigraz.at/>). Each virtual heart was paced sequentially from seven  
487 uniformly distributed endocardial LV locations using a validated rapid pacing protocol described  
488 in detail in previous studies.(Prakosa *et al.*, 2018; Arevalo *et al.*, 2016; Cartoski *et al.*, 2019)  
489 Similar to our work on VA risk stratifications for patients with ischemic  
490 cardiomyopathy,(Arevalo *et al.*, 2016) simulation results were analyzed to determine whether  
491 reentrant VA was induced in the LV HCM models following rapid pacing from any of the sites. If  
492 VA was induced from at least one pacing site in a given personalized HCM virtual heart, the  
493 patient was then considered at risk of VA. Simulation results were blind to clinical outcome.

494 The capability of our HCM virtual heart technology to predict VA risk was compared to  
495 risk scores for prophylactic ICD implantation developed by ACCF/AHA(Gersh *et al.*, 2011) and  
496 ESC(O'Mahony *et al.*, 2014) using the patient clinical data.

497

#### 498 **Funding:**

499 This work was supported by NIH grants R01HL142496 and R01HL126802 to N.T., a  
500 grant from the Leducq Foundation to N.T., an NIH T32 Fellowship (HL125239) to E.B., and a  
501 National Science Foundation Graduate Research Fellowship (DGE-1746891) to R.O.

502

#### 503 **Acknowledgments:**

504 The authors are grateful to Dr. Iacoppo Olivotto from Careggi University Hospital,  
505 Florence, Italy, for the inspiration and discussions.

506

507 **Disclosures:**

508 None.

509

510 **References:**

- 511 Arevalo, H. J., Vadakkumpadan, F., Guallar, E., Jebb, A., Malamas, P., Wu, K. C. and Trayanova,  
512 N. A. (2016) 'Arrhythmia risk stratification of patients after myocardial infarction using  
513 personalized heart models', *Nat Commun*, 7, pp. 11437.
- 514 Bayer, J. D., Blake, R. C., Plank, G. and Trayanova, N. A. (2012) 'A novel rule-based algorithm  
515 for assigning myocardial fiber orientation to computational heart models', *Ann Biomed En*,  
516 40(10), pp. 2243-2254.
- 517 Begg, G. A., Swoboda, P. P., Karim, R., Oesterlein, T., Rhode, K., Holden, A. V., Greenwood, J.  
518 P., Shantsila, E., Lip, G. Y. H., Plein, S. and Tayebjee, M. H. (2020) 'Imaging, biomarker and  
519 invasive assessment of diffuse left ventricular myocardial fibrosis in atrial fibrillation', *Journal of*  
520 *Cardiovascular Magnetic Resonance*, 22(1), pp. 13.
- 521 Bui, A. H., Roujol, S., Foppa, M., Kissinger, K. V., Goddu, B., Hauser, T. H., Zimetbaum, P. J.,  
522 Ngo, L. H., Manning, W. J., Nezafat, R. and Delling, F. N. (2017) 'Diffuse myocardial fibrosis in  
523 patients with mitral valve prolapse and ventricular arrhythmia', *Heart*, 103(3), pp. 204-209.
- 524 Cartoski, M. J., Nikolov, P. P., Prakosa, A., Boyle, P. M., Spevak, P. J. and Trayanova, N. A.  
525 (2019) 'Computational identification of ventricular arrhythmia risk in pediatric myocarditis',  
526 *Pediatr Cardiol*, 40(4), pp. 857-864.
- 527 Chu, L. C., Corona-Villalobos, C. P., Halushka, M. K., Zhang, Y., Pozzessere, C., Kamel, I. R.,  
528 Pozios, I., Van Der Geest, R. J., Gai, N., Abraham, R. M., Abraham, T. P., Bluemke, D. A. and  
529 Zimmerman, S. L. (2017) 'Structural and functional correlates of myocardial T1 mapping in 321  
530 patients with hypertrophic cardiomyopathy', *J Comput Assist Tomogr*, 41(4), pp. 653-660.
- 531 Coppini, R., Ferrantini, C., Yao, L., Fan, P., Del Lungo, M., Stillitano, F., Sartiani, L., Tosi, B.,  
532 Suffredini, S., Tesi, C., Yacoub, M., Olivotto, I., Belardinelli, L., Poggesi, C., Cerbai, E. and  
533 Mugelli, A. (2013) 'Late sodium current inhibition reverses electromechanical dysfunction in  
534 human hypertrophic cardiomyopathy', *Circulation*, 127(5), pp. 575-584.
- 535 Ellims, A. H., Iles, L. M., Ling, L., Chong, B., Macciocca, I., Slavin, G. S., Hare, J. L., Kaye, D.  
536 M., Marasco, S. F., McLean, C. A., James, P. A., du Sart, D. and Taylor, A. J. (2014) 'A  
537 comprehensive evaluation of myocardial fibrosis in hypertrophic cardiomyopathy with cardiac  
538 magnetic resonance imaging: linking genotype with fibrotic phenotype', *Eur Heart J*, 15(10), pp.  
539 1108-1116.
- 540 Ellims, A. H., Iles, L. M., Ling, L., Hare, J. L., Kaye, D. M. and Taylor, A. J. (2012) 'Diffuse  
541 myocardial fibrosis in hypertrophic cardiomyopathy can be identified by cardiovascular

542 magnetic resonance, and is associated with left ventricular diastolic dysfunction', *J Cardiovasc*  
543 *Magn Reson*, 14(1), pp. 76.

544 Galati, G., Leone, O., Pasquale, F., Olivotto, I., Biagini, E., Grigioni, F., Pilato, E., Lorenzini, M.,  
545 Corti, B., Foà, A., Agostini, V., Cecchi, F. and Rapezzi, C. (2016) 'Histological and Histometric  
546 Characterization of Myocardial Fibrosis in End-Stage Hypertrophic Cardiomyopathy: A Clinical-  
547 Pathological Study of 30 Explanted Hearts', *Circ Heart Fail*, 9(9), pp. e003090.

548 Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., Naidu, S. S.,  
549 Nishimura, R. A., Ommen, S. R., Rakowski, H., Seidman, C. E., Towbin, J. A., Udelson, J. E.  
550 and Yancy, C. W. (2011) 'American College of Cardiology Foundation/American Heart  
551 Association Task Force on Practice Guidelines. 2011 ACCF/AHA Guideline for the Diagnosis  
552 and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology  
553 Foundation/American Heart Association Task Force on Practice Guidelines. Developed in  
554 collaboration with the American Association for Thoracic Surgery, American Society of  
555 Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America,  
556 Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society  
557 of Thoracic Surgeons', *J Am Coll Cardiol*, 58(25), pp. e212-e260.

558 Iles, L., Pfluger, H., Phromminitikul, A., Cherayath, J., Aksit, P., Gupta, S. N., Kaye, D. M. and  
559 Taylor, A. J. (2008) 'Evaluation of diffuse myocardial fibrosis in heart failure with cardiac  
560 magnetic resonance contrast-enhanced T1 mapping', *J Am Coll Cardiol*, 52(19), pp. 1574-1580.

561 Jayatileke, I., Doolan, A., Ingles, J., McGuire, M., Booth, V., Richmond, D. R. and Semsarian,  
562 C. (2004) 'Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic  
563 cardiomyopathy', *American Journal of Cardiology*, 93(9), pp. 1192-1194.

564 Lambiase, P. D., Gold, M. R., Hood, M., Boersma, L., Theuns, D. A. M. J., Burke, M. C., Weiss,  
565 R., Russo, A. M., Kääb, S. and Knight, B. P. (2016) 'Evaluation of subcutaneous ICD early  
566 performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts',  
567 *Heart Rhythm*, 13(5), pp. 1066-1074.

568 Maron, B. J. (2004) 'Hypertrophic cardiomyopathy: an important global disease', *Am J Med*,  
569 116(1), pp. 63-63.

570 Mewton, N., Liu, C. Y., Croisille, P., Bluemke, D. and Lima, J. (2011) 'Assessment of myocardial  
571 fibrosis with cardiac magnetic resonance', *J Am Coll Cardiol*, 57(8), pp. 891-903.

572 Nakamori, S., Bui, A. H., Jang, J., El-Rewaidy, H. A., Kato, S., Ngo, L. H., Josephson, M. E.,  
573 Manning, W. J. and Nezafat, R. (2018) 'Increased myocardial native T1 relaxation time in  
574 patients with nonischemic dilated cardiomyopathy with complex ventricular arrhythmia', *Journal*  
575 *of Magnetic Resonance Imaging*, 47(3), pp. 779-786.

576 O'Mahony, C., Jichi, F., Pavlou, M., Monserrat, L., Anastasakis, A., Rapezzi, C., Biagini, E.,  
577 Gimeno, J. R., Limongelli, G., McKenna, W. J., Omar, R. Z. and Elliott, P. M. (2014) 'A novel  
578 clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM  
579 risk-SCD)', *Eur Heart J*, 35(30), pp. 2010-2020.

580 Olivotto, I., Cecchi, F., Poggesi, C. and Yacoub, M. H. (2012) 'Patterns of disease progression in  
581 hypertrophic cardiomyopathy: An individualized approach to clinical staging', *Circ Heart Fail*,  
582 5(4), pp. 535-546.

583 O'Hara, T., Virág, L., Varró, A. and Rudy, Y. (2011) 'Simulation of the undiseased human cardiac  
584 ventricular action potential: model formulation and experimental validation', *PLoS Comput Biol*,  
585 7(5), pp. e1002061.

586 Plank, G., Zhou, L., Greenstein, J., Cortassa, S., Winslow, R., O'Rourke, B. and Trayanova, N.  
587 (2008) 'From mitochondrial ion channels to arrhythmias in the heart: computational techniques  
588 to bridge the spatio-temporal scales', *Philos Trans A Math Phys Eng Sci*, 366(1879).  
589 Prakosa, A., Arevalo, H. J., Deng, D., Boyle, P. M., Nikolov, P. P., Ashikaga, H., Blauer, J. J. E.,  
590 Ghafoori, E., Park, C. J., Blake III, R. C., Han, F. T., MacLeod, R. S., Halperin, H. R., Callans,  
591 D. J., Ranjan, R., Chrispin, J., Nazarian, S. and Trayanova, N. A. (2018) 'Personalized virtual-  
592 heart technology for guiding the ablation of infarct-related ventricular tachycardia', *Nat Biomed*  
593 *Eng*, 2, pp. 732-740.  
594 Prakosa, A., Malamas, P., Zhang, S., Pashakhanloo, F., Arevalo, H., Herzka, D. A., Lardo, A.,  
595 Halperin, H., McVeigh, E., Trayanova, N. and Vadakkumpadan, F. (2014) 'Methodology for  
596 image-based reconstruction of ventricular geometry for patient-specific modeling of cardiac  
597 electrophysiology', *Progress in Biophysics and Molecular Biology*, 115(2), pp. 226-234.  
598 Prassl, A. J., Kickinger, F., Ahammer, H., Grau, V., Schneider, J. E., Hofer, E., Vigmond, E. J.,  
599 Trayanova, N. A. and Plank, G. (2009) 'Automatically generated, anatomically accurate meshes  
600 for cardiac electrophysiology problems', *IEEE Trans Biomed Eng*, 56(5), pp. 1318-1330.  
601 Schinkel, A. F. L., Vriesendorp, P. A., Sijbrands, E. J. G., Jordaens, L. J. L. M., ten Cate, F. J. and  
602 Michels, M. (2012) 'Outcome and complications after implantable cardioverter defibrillator  
603 therapy in hypertrophic cardiomyopathy', *Circ Heart Fail*, 5, pp. 552-559.  
604 Shade, J. K., Ali, R. L., Basile, D., Popescu, D., Akhtar, T., Marine, J. E., Spragg, D. D., Calkins,  
605 H. and Trayanova, N. A. (2020a) 'Preprocedure Application of Machine Learning and  
606 Mechanistic Simulations Predicts Likelihood of Paroxysmal Atrial Fibrillation Recurrence  
607 Following Pulmonary Vein Isolation', *Circulation: Arrhythmia and Electrophysiology*, 13(7).  
608 Shade, J. K., Cartoski, M. J., Nikolov, P., Prakosa, A., Doshi, A., Binka, E., Olivieri, L., Boyle, P.  
609 M., Spevak, P. J. and Trayanova, N. A. (2020b) 'Ventricular arrhythmia risk prediction in  
610 repaired tetralogy of fallot using personalized computational cardiac models', *Heart Rhythm*,  
611 17(3), pp. 408-414.  
612 Shade, J. K., Prakosa, A., Popescu, D. M., Yu, R., Okada, D. R., Chrispin, J. and Trayanova, N.  
613 A. (2021) 'Predicting risk of sudden cardiac death in patients with cardiac sarcoidosis using  
614 multimodality imaging and personalized heart modeling in a multivariable classifier', *Science*  
615 *Advances*, 7(31), pp. eabi8020.  
616 ten Tusscher, K. H. W. J. and Panfilov, A. V. (2006) 'Alternans and spiral breakup in a human  
617 ventricular tissue model', *Am J Physiol Heart Circ Physiol*, 291(3), pp. H1088-H1100.  
618 Vigmond, E., Weber dos Santos, R., Prassl, A., Deo, M. and Plank, G. (2008) 'Solvers for the  
619 cardiac bidomain equations', *Prog Biophys Mol Biol*, 96(1-3), pp. 3-18.  
620